Bryan Garnier - ONWARD OPPORTUNITIES LIMITED (ONWD) ONWARD Medical: Q1 2024 delivered as promised

Report

Bryan Garnier

Maria Vara

ONWARD Medical: Q1 2024 delivered as promised

This morning, ONWARD provided a snapshot of Q1 2024 achievements and, while nothing came as a surprise, we appreciate the productive quarter and positive progress from clinical and financial angles. As summarized in the strategic priorities for 2024 disclosed early this year (read our note here), t

23/05/2024 1 EN

Underlying

ONWARD OPPORTUNITIES LIMITED

See profile

GG00BMZR1514 London Stock Exchange Guernsey

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Maria Vara

Other Reports on these Companies

Bryan Garnier

ONWARD Medical: EIC grant expands ARC-BCI development to subcortical stroke

This morning, ONWARD Medical announced that it had secured a significant grant from the European Innovation Council (EIC) to investigate and develop ARC-BCI Therapy aimed at restoring upper limb function in patients with subcortical stroke. While SCI-related movement disorders remain the company’s

November 19, 2024 November 19, 2024 1 EN

Bryan Garnier

ONWARD Medical: ARC-EX recognised as one of TIME's Best Inventions of 2024

ONWARD Medical's investigational ARC-EX System was named one of TIME's Best Inventions of 2024, spotlighting its potential to improve life for SCI. Recognised for originality, efficacy, ambition, and impact, the ARC-EX System enables SCI patients to regain hand and arm function, as evidenced by the

October 31, 2024 October 31, 2024 1 EN

Bryan Garnier

ONWARD Medical: successful EUR50m upsized raise with Ottobock as cornerstone investor

ONWARD Medical successfully secured a capital raise of EUR50m in total gross proceeds through an upsized bookbuild offering via a private placement. Ottobock contributed EUR22.5m as a strategic cornerstone investor, with the potential for synergistic value creation in both the near and long term. T

October 24, 2024 October 24, 2024 1 EN

Cinclus: agreement with the FDA on the iPSP

Similar to the agreement for the PIP concluded with the EU's EMA a couple of weeks ago, Cinclus has reached an agreement with the FDA on the company’s initial Paediatric Study Plan (iPSP) for linaprazan glurate, which is a prerequisite for market approval for adult use in the US. The study plan wil

21h / 3m 21h / 3m 1 EN

Maria Vara

Maria Vara

BICO: divests Nanoscribe for EUR26m in line with BICO 2.0 Strategy

BICO has agreed to sell Nanoscribe to LAB14 GmbH for an equity value of EUR26m (SEK294m), with the transaction set to close in Q4 2024. We are pleased to see the company executing the BICO 2.0 strategy shared during CMD 2024, which designates Nanoscribe as non-core due to its primary focus outside

21h / 13m 21h / 13m 1 EN

Aurelien Deside

Aurelien Deside

Exclusive Networks: expanding into the US with Cloudrise acquisition

Yesterday evening, Exclusive Networks announced the acquisition of 100% of Cloudrise, a security services provider headquartered in the USA. This acquisition represents a positive step towards the continued penetration of the highly attractive US cybersecurity market, which the group sees as a key

21h / 14m 21h / 14m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

ONWARD Medical: Q1 2024 delivered as promised

ONWARD Medical: EIC grant expands ARC-BCI development to subcortical stroke

ONWARD Medical: ARC-EX recognised as one of TIME's Best Inventions of 2024

ONWARD Medical: successful EUR50m upsized raise with Ottobock as cornerstone investor

Cinclus: agreement with the FDA on the iPSP

BICO: divests Nanoscribe for EUR26m in line with BICO 2.0 Strategy

Exclusive Networks: expanding into the US with Cloudrise acquisition

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe